Captor Therapeutics SA

NEW
WAR:CTX (Poland)  
zł 34.5 -2.5 (-6.76%) Apr 7
At Loss
P/B:
4.20
Market Cap:
zł 160.87M ($ 40.92M)
Enterprise V:
zł 117.57M ($ 29.91M)
Volume:
6.03K
Avg Vol (2M):
4.04K
Warning! GuruFocus detected 3 Severe warning signs with CTX. Try a 7-Day Free Trial to check it out.
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
6.03K
Market Cap zł:
160.87M
Market Cap $:
40.92M
At Loss
Avg Vol (2M):
4.04K
Enterprise Value zł:
117.57M
Enterprise Value $:
29.91M
PB Ratio:
4.20
Website Sources Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocksâ„¢

Business Description

Captor Therapeutics SA

ISIN : PLCPTRT00014
http://www.captortherapeutics.com
ul. Dunska 11, Wroclaw, POL, 54-427
Compare
Compare
WAR:MOCWAR:PTGWAR:MABWAR:URTWAR:NNGWAR:BIOWAR:RDGWAR:PHRWAR:PURWAR:SVEVRTXASX:CSLREGNXKRX:207940XBRU:ARGXALNYXBRU:UCBONCXKRX:068270BNTX
Traded in other countries / regions
CTX.Poland60Q.Germany
IPO Date
2021-04-19
Description
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.

Financial Strength

4/10
Name Current Vs Industry Vs History
Cash-To-Debt 8.84
Equity-to-Asset 0.64
Debt-to-Equity 0.13
Debt-to-EBITDA -0.15
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.95
Distress
Grey
Safe
Beneish M-Score -2.02
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -98
3-Year EPS without NRI Growth Rate -57.4
3-Year FCF Growth Rate -260
Future 3-5Y Total Revenue Growth Rate Estimate 86.01

Momentum Rank

4/10
Name Current Vs Industry Vs History
5-Day RSI 18.1
9-Day RSI 23.43
14-Day RSI 26.51
3-1 Month Momentum % 1.83
6-1 Month Momentum % -39.04
12-1 Month Momentum % -35.51

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.65
Quick Ratio 2.65
Cash Ratio 2.34
Days Sales Outstanding 83.82
Days Payable 296.44

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -12.6
Shareholder Yield % -22.59

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 57.02
Operating Margin % -215.71
Net Margin % -212.61
FCF Margin % -212.64
ROE % -78.66
ROA % -52.01
ROIC % -155.44
3-Year ROIIC % 4211.65
ROC (Joel Greenblatt) % -539.47
ROCE % -75.22

GF Value Rank

2/10
Name Current Vs Industry Vs History
Forward PE Ratio 74
PS Ratio 9.85
PB Ratio 4.2
Price-to-Tangible-Book 4.03
EV-to-EBIT -2.88
EV-to-EBITDA -3.29
EV-to-Revenue 6.08
EV-to-FCF -3.14
Price-to-GF-Value 0.12
Price-to-Net-Current-Asset-Value 5.07
Price-to-Net-Cash 6.35
Earnings Yield (Greenblatt) % -34.68
FCF Yield % -25.59

Financials (Next Earnings Date:2025-05-29 Est.)

WAR:CTX's 30-Y Financials
AAPL
Income Statement Breakdown FY
Not Enough Data
AAPL
Balance Sheet Breakdown
Not Enough Data
AAPL
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Captor Therapeutics SA Executives

Details

GF Value: zł287.63

WAR:CTX

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil zł) 19.356
EPS (TTM) (zł) -7.5
Beta 0.96
3-Year Sharpe Ratio -0.92
3-Year Sortino Ratio -1.13
Volatility % 56.05
14-Day RSI 26.51
14-Day ATR (zł) 2.325845
20-Day SMA (zł) 39.97
12-1 Month Momentum % -35.51
52-Week Range (zł) 31.5 - 86.4
Shares Outstanding (Mil) 4.66

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Captor Therapeutics SA Filings

Filing Date Document Date Form
No Filing Data

Captor Therapeutics SA Stock Events

Financials Calendars
Event Date Price (zł)
No Event Data

Captor Therapeutics SA Frequently Asked Questions

What is Captor Therapeutics SA(WAR:CTX)'s stock price today?
The current price of WAR:CTX is zł34.50. The 52 week high of WAR:CTX is zł86.40 and 52 week low is zł31.50.
When is next earnings date of Captor Therapeutics SA(WAR:CTX)?
The next earnings date of Captor Therapeutics SA(WAR:CTX) is 2025-05-29 Est..
Does Captor Therapeutics SA(WAR:CTX) pay dividends? If so, how much?
Captor Therapeutics SA(WAR:CTX) does not pay dividend.

Press Release

Subject Date
No Press Release
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.